Table 3 Incidence of adverse events associated with traditional NSAIDs or iCOX2 compared to placebo in patients with axSpA: meta-analysis of randomized clinical trials
|
TRADITIONAL NSAIDs N=1289 |
iCOX2 N=669 | |
|---|---|---|
| Adverse events |
35.6% vs 36.4% (PbO) RR=1.08 (0.93 to 1.25) |
54.6% vs 46.4% (PbO) RR=1.22 (0.93 to 1.62) |
| Severe adverse events |
1% vs 0.6% (PbO) RR=1.71 (0.37 to 8.01) |
0.6% vs 0.6% (PbO) RR=0.96 (0.17 to 5.53) |
| Gastrointestinal adverse events |
18% vs 9.5% (PbO) RR=1.92 (1.41 to 2.61) |
17.7% vs 7.5% (PbO) RR=2.55 (1.92 to 4.95) |
| Discontinuation due to adverse events |
5% vs 5.5% (PbO) RR=0.76 (0.48 to 1.22) |
4.6% vs 3.4% (PbO) RR=2.14 (0.36 to 12.56) |